PE20141579A1 - Nuevos 2h-indazoles como antagonistas del receptor ep2 - Google Patents
Nuevos 2h-indazoles como antagonistas del receptor ep2Info
- Publication number
- PE20141579A1 PE20141579A1 PE2014000760A PE2014000760A PE20141579A1 PE 20141579 A1 PE20141579 A1 PE 20141579A1 PE 2014000760 A PE2014000760 A PE 2014000760A PE 2014000760 A PE2014000760 A PE 2014000760A PE 20141579 A1 PE20141579 A1 PE 20141579A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- alkyl
- residue
- members
- indazoles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
SE REFIERE A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES H, ALQILO C1-C2 O ALQUIL C1-C2-XILO; R2 ES H O METILO; R4 ES H, ALQUILO C1-C4, CICLOALQUILO C3-C4 O CH2-CICLOALQUILO C3-C4; X JUNTO CON R4 FORMAN UN RESIDUO DE HETEROCICLILO DE 4-6 MIEMBROS POR MEDIO DE UNA LIGACION DE CARBONO DE ANILLO; m ES 1 O 2; n ES 1 O 2; Ar ES UN RESIDUO DE ARILO DE 6-10 MIEMBROS O RESIDUO DE HETARILO DE 5 A 10 MIEMBROS; R3 ES HALOGENO, CN, SF5, ALQUILO C1-C4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-{[1-(4-CIANO-2-FLUOROBENZOIL)PIPERIDIN-4-IL]METIL}-N-(2-METOXIETIL)-4-METIL-2H-INDAZOL-5-CARBOXAMIDA; N-(2-METOXIETIL)-4-METIL-2-{[1-(4-MORFOLINOBENZOIL)PIPERIDIN-4-IL]METIL}-2H-INDAZOL-5-CARBOXAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO PARA LA PREPARACION DE DICHOS COMPUESTOS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011087170 | 2011-11-28 | ||
DE102012206715 | 2012-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141579A1 true PE20141579A1 (es) | 2014-11-15 |
Family
ID=47278803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014000760A PE20141579A1 (es) | 2011-11-28 | 2012-11-26 | Nuevos 2h-indazoles como antagonistas del receptor ep2 |
Country Status (25)
Country | Link |
---|---|
US (1) | US9062041B2 (es) |
EP (1) | EP2785707B1 (es) |
JP (1) | JP6192654B2 (es) |
KR (1) | KR20140103984A (es) |
CN (1) | CN104144922B (es) |
AR (1) | AR089011A1 (es) |
AU (1) | AU2012344015A1 (es) |
BR (1) | BR112014012459A2 (es) |
CA (1) | CA2856769A1 (es) |
CL (1) | CL2014001392A1 (es) |
CO (1) | CO6970595A2 (es) |
CR (1) | CR20140257A (es) |
DO (1) | DOP2014000114A (es) |
EA (1) | EA201400623A1 (es) |
EC (1) | ECSP14002542A (es) |
ES (1) | ES2665510T3 (es) |
HK (1) | HK1203938A1 (es) |
IL (1) | IL232503A (es) |
IN (1) | IN2014CN03854A (es) |
MX (1) | MX2014006433A (es) |
PE (1) | PE20141579A1 (es) |
PH (1) | PH12014501195A1 (es) |
SG (1) | SG11201402269RA (es) |
TW (1) | TW201326154A (es) |
WO (1) | WO2013079425A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR087814A1 (es) | 2011-09-16 | 2014-04-16 | Fovea Pharmaceuticals | Derivados de anilina, su preparacion y su aplicacion terapeutica |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
WO2014187744A1 (de) | 2013-05-23 | 2014-11-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische zusammensetzung und deren verwendung sowie anwendungsregime dieser pharmazeutischen zusammensetzung zur bedarfsweisen („on-demand") kontrazeption |
WO2014187793A1 (de) * | 2013-05-23 | 2014-11-27 | Bayer Pharma Aktiengesellschaft | Verwendung einer pharmazeutischen zusammensetzung zur notfallkontrazeption |
CA2951259A1 (en) | 2014-06-06 | 2015-12-10 | Flexus Biosciences, Inc. | Immunoregulatory agents |
UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
EP3215141A4 (en) | 2014-11-05 | 2018-06-06 | Flexus Biosciences, Inc. | Immunoregulatory agents |
EP3877384A1 (en) | 2018-11-08 | 2021-09-15 | GlaxoSmithKline Intellectual Property Development Ltd | Chemical compounds |
JPWO2022138792A1 (es) * | 2020-12-24 | 2022-06-30 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI9710372B8 (pt) | 1996-07-18 | 2021-05-25 | Merck Canada Inc | composto, e, composição farmacêutica. |
US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
HN2001000224A (es) * | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
JP4529119B2 (ja) | 2001-08-09 | 2010-08-25 | 小野薬品工業株式会社 | カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤 |
WO2003030911A1 (en) | 2001-10-08 | 2003-04-17 | Medical Research Council | Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus |
ES2305310T3 (es) | 2001-10-23 | 2008-11-01 | Laboratoires Serono Sa | Compuestos de pirazolidinona como ligandos de los receptores de ep2 y/o ep4 de prostaglandinas. |
ES2292814T3 (es) | 2001-10-31 | 2008-03-16 | Medical Research Council | Antagonistas de los receptores ep2 y/o ep4 de la prostaglandina para el tratamiento de la menorragia. |
ES2337887T3 (es) | 2001-12-20 | 2010-04-30 | Merck Serono Sa | Derivados de pirrolidina en calidad de moduladores de prostaglandina. |
CN1625549A (zh) | 2002-01-31 | 2005-06-08 | 辉瑞产品公司 | (3-{[4-叔丁基-苄基)-(吡啶-3-磺酰基)-氨基]-甲基}-苯氧基)-乙酸的代谢物 |
JP4547912B2 (ja) | 2002-03-05 | 2010-09-22 | 小野薬品工業株式会社 | 8−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤 |
WO2004032964A1 (ja) | 2002-10-10 | 2004-04-22 | Ono Pharmaceutical Co., Ltd. | アレルギー性疾患治療剤 |
DK1866292T3 (da) | 2005-03-31 | 2011-05-09 | Auckland Uniservices Ltd | Tricykliske 1,2,4-triazinoxider og sammensætninger deraf til terapeutisk anvendelse i cancerbehandlinger |
PT1816121E (pt) | 2005-11-21 | 2008-05-28 | Bayer Schering Pharma Ag | Derivados de 9-cloro-15-desoxiprostaglandina, processo para a sua preparação e sua utilização como medicamentos |
DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
EP1986643A1 (en) | 2006-02-10 | 2008-11-05 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
EP1884906A1 (de) | 2006-07-31 | 2008-02-06 | Siemens Building Technologies Fire & Security Products GmbH & Co. oHG | Levelsynchronisation bei Funk-Kommunikationsnetzwerken |
EP1903038A1 (de) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
EP1900731A1 (de) | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
EP1903037A1 (de) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors |
KR20090127867A (ko) | 2006-12-05 | 2009-12-14 | 네이셔널 치아오 텅 유니버시티 | 인다졸 화합물 |
WO2008139287A1 (en) | 2007-05-10 | 2008-11-20 | Pfizer Limited | Azetidine derivatives and their use as prostaglandin e2 antagonists |
EP2003119A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Acetamide als Modulatoren des EP2-Rezeptors |
EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
EP2002834A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
EP2014663A1 (de) | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine als Modulatoren des EP2-Rezeptors |
EP2014662A1 (de) | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Indolylalkylthienopyrimidylamine als Modulatoren des EP2-Rezeptors |
CA2705368A1 (en) * | 2007-11-15 | 2009-05-22 | Pfizer Limited | Azetidines as ep2 antagonists |
US8598355B2 (en) * | 2008-05-14 | 2013-12-03 | Astellas Pharma Inc. | Amide compound |
WO2010008777A2 (en) | 2008-06-23 | 2010-01-21 | Ligand Pharmaceuticals Inc. | Fused azabicyclic pyridines |
MX2011004903A (es) | 2008-11-10 | 2011-05-30 | Pfizer Ltd | Pirrolidinas. |
EP2379524A1 (en) * | 2008-12-18 | 2011-10-26 | Boehringer Ingelheim International GmbH | Serotonin 5-ht2b receptor inhibitors |
TW201107315A (en) * | 2009-07-27 | 2011-03-01 | Kissei Pharmaceutical | Indole derivatives, or the pharmaceutically acceptable salts |
DE102009049662A1 (de) | 2009-10-13 | 2011-04-14 | Bayer Schering Pharma Aktiengesellschaft | 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
-
2012
- 2012-11-16 TW TW101142970A patent/TW201326154A/zh unknown
- 2012-11-26 SG SG11201402269RA patent/SG11201402269RA/en unknown
- 2012-11-26 BR BR112014012459A patent/BR112014012459A2/pt active Search and Examination
- 2012-11-26 IN IN3854CHN2014 patent/IN2014CN03854A/en unknown
- 2012-11-26 EP EP12794931.1A patent/EP2785707B1/en not_active Not-in-force
- 2012-11-26 KR KR1020147017230A patent/KR20140103984A/ko not_active Application Discontinuation
- 2012-11-26 JP JP2014542872A patent/JP6192654B2/ja not_active Expired - Fee Related
- 2012-11-26 EA EA201400623A patent/EA201400623A1/ru unknown
- 2012-11-26 ES ES12794931.1T patent/ES2665510T3/es active Active
- 2012-11-26 CN CN201280067965.1A patent/CN104144922B/zh not_active Expired - Fee Related
- 2012-11-26 US US14/361,213 patent/US9062041B2/en not_active Expired - Fee Related
- 2012-11-26 WO PCT/EP2012/073556 patent/WO2013079425A1/en active Application Filing
- 2012-11-26 CA CA2856769A patent/CA2856769A1/en not_active Abandoned
- 2012-11-26 MX MX2014006433A patent/MX2014006433A/es not_active Application Discontinuation
- 2012-11-26 AU AU2012344015A patent/AU2012344015A1/en not_active Abandoned
- 2012-11-26 PE PE2014000760A patent/PE20141579A1/es not_active Application Discontinuation
- 2012-11-28 AR ARP120104465A patent/AR089011A1/es active Pending
-
2014
- 2014-05-08 IL IL232503A patent/IL232503A/en not_active IP Right Cessation
- 2014-05-27 CL CL2014001392A patent/CL2014001392A1/es unknown
- 2014-05-27 PH PH12014501195A patent/PH12014501195A1/en unknown
- 2014-05-28 CO CO14115091A patent/CO6970595A2/es unknown
- 2014-05-28 EC ECIEPI20142542A patent/ECSP14002542A/es unknown
- 2014-05-28 CR CR20140257A patent/CR20140257A/es unknown
- 2014-05-28 DO DO2014000114A patent/DOP2014000114A/es unknown
-
2015
- 2015-05-07 HK HK15104364.3A patent/HK1203938A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN104144922A (zh) | 2014-11-12 |
JP2014533713A (ja) | 2014-12-15 |
EP2785707A1 (en) | 2014-10-08 |
WO2013079425A1 (en) | 2013-06-06 |
CL2014001392A1 (es) | 2014-10-03 |
IL232503A (en) | 2015-08-31 |
KR20140103984A (ko) | 2014-08-27 |
BR112014012459A2 (pt) | 2017-06-06 |
US20140336172A1 (en) | 2014-11-13 |
ES2665510T3 (es) | 2018-04-26 |
PH12014501195A1 (en) | 2014-09-01 |
CA2856769A1 (en) | 2013-06-06 |
CR20140257A (es) | 2014-07-15 |
MX2014006433A (es) | 2014-07-11 |
CN104144922B (zh) | 2016-08-31 |
JP6192654B2 (ja) | 2017-09-06 |
IL232503A0 (en) | 2014-07-01 |
NZ624722A (en) | 2016-08-26 |
AU2012344015A1 (en) | 2014-05-29 |
EA201400623A1 (ru) | 2014-11-28 |
IN2014CN03854A (es) | 2015-09-04 |
SG11201402269RA (en) | 2014-09-26 |
ECSP14002542A (es) | 2015-12-31 |
TW201326154A (zh) | 2013-07-01 |
DOP2014000114A (es) | 2014-07-15 |
HK1203938A1 (en) | 2015-11-06 |
AR089011A1 (es) | 2014-07-23 |
EP2785707B1 (en) | 2018-01-24 |
CO6970595A2 (es) | 2014-06-13 |
US9062041B2 (en) | 2015-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141579A1 (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
PE20130155A1 (es) | Derivados de ariletinilo | |
PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
CR10784A (es) | Nuevos derivados de aminopirimidina como inhibidores de plki | |
PE20130279A1 (es) | Compuestos heteroarilo nitrogenados | |
ES2640911T3 (es) | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus | |
ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
CR20110049A (es) | Derivados de benzazepina y su uso como antagonistas de histamina h3 | |
AR080688A1 (es) | Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina | |
MX368178B (es) | Compuestos de ácido dimetilbenzoico. | |
PE20160589A1 (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a | |
ES2421896T3 (es) | Compuestos de aril-(imidazol)-metil-fenilo sustituidos como moduladores selectivos de los subtipos de receptores adrenérgicos alfa 2B y/o alfa 2C | |
DOP2010000226A (es) | Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos | |
ECSP14013296A (es) | Derivados de etinilo | |
MY152281A (en) | 4-pyrimidinesulfamide derivative | |
AR086554A1 (es) | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina | |
AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
RS54488B1 (en) | NALOXOL-POLYETHYLENE GLYCOL CRYSTAL CONJUGATE | |
DK2197860T3 (da) | Nye forbindelser som adenosin-A1-receptorantagonister | |
AR103317A1 (es) | Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina | |
ECSP13012980A (es) | Derivados de fenil- o piridinil-etinilo | |
ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
CL2010000253A1 (es) | Procedimiento de preparacion de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable; y uno de los compuestos intermediarios considerados. | |
CR20130541A (es) | Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como receptores vegf de inhibidores de cinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |